期刊文献+

血清HE4和CA125联合预测卵巢肿瘤的风险 被引量:5

Prediction Risk of Ovarian Malignancy with Serum HE4 and CA125
下载PDF
导出
摘要 目的通过联合检测患者血清中的人附睾蛋白4(HE4)和癌抗原125(CA125),建立一种简单、有效的卵巢肿瘤患者风险预测模型。方法采用化学发光微粒子法(CMIA)测定257例女性血清的CA125、HE4水平,其中盆腔肿瘤患者按术后病理结果分为良性病变组111例和卵巢癌组53例;体检健康女性93例作为正常对照。对所有结果进行统计分析,并通过预测公式分别计算绝经前、后妇女患卵巢癌的风险。结果卵巢癌组CA125和HE4水平明显高于良性病变组和正常对照组(P<0.01);而相比正常对照组,良性病变组CA125水平稍有升高(48.2±127.0 vs 15.9±22.0IU/ml,P>0.05),HE4水平几乎没有变化(47.5±11.0 vs 42.6±8.0pmol/L,P>0.05)。绝经前组77例良性患者中67例被预测为低风险人群,预测特异性为87%;而35例卵巢癌病人有29例被预测为高风险患者,预测敏感性为82.9%;同理,绝经后组34例良性患者中27例被预测为低风险人群,预测特异性为79.4%,而18例卵巢癌病人有15例被预测为高风险患者,预测敏感性为83.3%。结论该模型综合利用血清CA125和HE4水平,成功将83%的卵巢癌患者归类为高风险人群,是临床上辅助卵巢肿瘤诊断、监测和术后风险预知的较好模型。 Objective To establish a simple and effective model for prediction risk of patients with ovarian neoplasm with human ep- ididymis protein 4 (HE4) and cancer antigen 125 (CA125). Methods Serum CA125 and HE4 levels in 257 cases were measured by chemiluminescent microparticle immunoassay (CMIA). Among them, 111 cases were divided into benign lesions and 53 patients were classified as ovarian cancer according to pathological diagnosis, while 93 cases healthy women were chosen as normal controls. Data were processed by statistical analysis, and premenopausal/postmenopausal women were categorized into low or high risk candidates using corre- sponding prediction equations. Results CA125 and HE4 levels in ovarian cancer group were significantly higher than benign lesions or normal group (P 〈0.05). Compared to normal ones, there showed a slightly elevation for CA125 in benign lesions (48.2 ± 127.0 vs 15.9 ± 22. OIU/ml, P 〉 0.05 ) , while HE4 remained nearly unchanged (47.5 ± 11.0 vs 42.6 ± 8. 0pmol/L, P 〉 0. 05 ). In premenopausal group, 67 of 77 benign cases were predicted as the low - risk populations, with a predictive specificity of 87% ; among 35 ovarian canc- er cases, 29 were forecasted to be high -risk patients, giving a sensitivity of 82.9%. Similarly, 27 of 34 postmenopausal benign patients were predicted as the low- risk populations, with a forecast specificity of 79.4% , and 15 of 18 ovarian cancer cases were classified as high - risk patients, providing a sensitivity of 83.3%. Conclusion These equations with serum CA125 and HE4 levels successfully cate- gorize 83% ovarian cancer patients into high -risk group, thus is believed to be a promising model for clinical ovarian cancer auxiliary di- agnosis, postoperative monitoring as well as risk prediction.
出处 《医学研究杂志》 2012年第7期150-153,共4页 Journal of Medical Research
关键词 卵巢肿瘤 人附睾蛋白4(HE4) 癌抗原125(CA125) Ovarian neoplasm Human epididymis protein 4 (HE4) Cancer antigen 125 (CA125)
  • 相关文献

参考文献12

  • 1Rauh - Hain JA, Krivak TC, Del Carmen MG, et al. Ovarian cancer screening and early detection in the general population [ J ]. Rev Obstet Gynecol, 2011,4(1) : 15 -21. 被引量:1
  • 2Kenemans P, Yedema CA, Bon GG, et al. CA 125 in gynecological pathology - a review[ Jl. Eur J Obstet Gynecol Reprod Biol, 1993,49 (1 -2): 115-124. 被引量:1
  • 3Park Y, Lee JH, Hong D J, et al. Diagnostic performances of HEal and CA125 for the detection of ovarian cancer from patients with vari- ous gynecologic and non - gynecologic diseases [ J 1 - Clin Biochem, 2011,44(10-11): 884 -888. 被引量:1
  • 4Rosen DG, Wang L, Atkinson JN, et al. Potential markers that com- plement expression of CA125 in epithelial ovarian cancer[ J]. Gynecol Oncol, 2005,99 (2) : 267 - 277. 被引量:1
  • 5Steffensen KD, Waldstrom M, Brandslund I, et al. Prognostic impact of prechemotherapy serum levels of HER2, CA125, and HE4 in ovari- an cancer patients [ J ]. Int J Gynecol Cancer, 2011,21 ( 6 ) : 1040 - 1047. 被引量:1
  • 6Hagen B, Tingulstad S, Onsrud M, et al. Preoperative identification of malignancy among women with a pelvic mass. Evaluation of a risk index based on ultrasound findings. CA 125 in serum and menopausal status[J]. Tidsskr Nor Laegeforen, 1995,115 ( 7 ) : 820 - 822. 被引量:1
  • 7Moore RG, Brown AK, Miller MC, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass[J]. Gynecol Oncol, 2008,108(2) : 402 -408. 被引量:1
  • 8Bailey J, Tailor A, Naik R, et al. Risk of malignancy index for refer- ral of ovarian cancer cases to a tertiary center: does it identify the cor- rect cases? [J]. Int J Gynecol Cancer, 2006,16 Suppl 1 : 30 -34. 被引量:1
  • 9Kirchhoff C, Habben I, Ivell R, et al. A major human epididymis - specific cDNA encodes a protein with sequence homology to extracellu- lar proteinase inhibitors[ J]. Biol Reprod, 1991,45(2) : 350 -357. 被引量:1
  • 10Li J, Dowdy S, Tipton T, et al. HE4 as a biomarker for ovarian and endometrial cancer management[J]. Expert Rev Mol Diagn, 2009,9 (6) : 555 -566. 被引量:1

同被引文献49

  • 1楼海亚,孟华,朱庆莉,张青,姜玉新.四种恶性风险指数在附件肿块良恶性诊断中的应用价值[J].中国医学科学院学报,2010,32(3):297-302. 被引量:10
  • 2Yip P,Chen TH,Seshaiah P,et al. Comprehensive serum profiling for the diseovery of epithelial ovarian cancer biomarkers [ J ]. PLoS One,2011,6 ( 12 ) :e29533. 被引量:1
  • 3Nolen BM, Lokshin AE. Protein biomarkers of ovarian cancer: the forest and the trees[J]. Future Oncol,2012,8( 1 ) :55-71. 被引量:1
  • 4Thakur A, Mishra V, Jain SK. Feed forward artificial neural net- work: tool for early detection of ovarian cancer [ J ]. Sci Pharm, 2011,79 (3) :493-505. 被引量:1
  • 5Partheen K, Kristjansdottir B, Sundfeldt K. Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a sus- picious cystic ovarian mass [ J ]. J Gynecol Oncol, 2011 , 22 ( 4 ) : 244-252. 被引量:1
  • 6Van Gorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diag- nostic test in ovarian cancer: prospective validation of the Risk of O- varian Malignancy Algorithm [ J ]. Br J Cancer, 2011 , 104 ( 5 ) : 863 -870. 被引量:1
  • 7Li F,Tie R,Chang K,et al. Does risk for ovarian malignancy algo- rithm excel human epididymis protein 4 and CA125 in predicting ep- ithelial ovarian cancer: a meta-analysis [ J ]. BMC Cancer, 2012, 12:258. 被引量:1
  • 8Kalantri Y,Naik G,Joshi SP,et al. Role of cancer antigen-125 from pleural & ascitic fluid samples in non malignant conditions[ Jl. Indi- an J Med Res,2007,125:25-30. 被引量:1
  • 9Kalapotharakos G, Asciutto C, Henic E, et al. High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer[ J]. J Ovarian Res,2012,5(1):20. 被引量:1
  • 10Kirchhoff C, Habben I, Ivell R. A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular pro- teinase inhibitors [ J ]. Biology of Reproduction, 1991,45 ( 2 ) : 350 - 357. 被引量:1

引证文献5

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部